Geron Corporation (GERN)
Geron: Time To Reconsider This Oversold Biotech
Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026 revenues of $220–$240 million and is executing targeted commercial and European expansion strategies. A new management team is in place, with significant liquidity ($341 million) and a cash runway of ~2.7 years supporting ongoing pipeline and commercial efforts.
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Geron: Minimal Sales Growth But A Potential Run-Up Ahead
Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-$240M, implying 25% growth. Key catalysts include a potential IMpactMF interim readout in H2 '26 and readouts from investigator-sponsored trials and potential real-world data that could encourage use of Rytelo.
Almitas Capital LLC Buys Shares of 946,323 Geron Corporation $GERN
Almitas Capital LLC bought a new position in Geron Corporation (NASDAQ: GERN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 946,323 shares of the biopharmaceutical company's stock, valued at approximately $1,296,000. Almitas Capital LLC owned about 0.15% of Geron at the
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings
Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategic restructuring and workforce reductions reflect a pivot toward financial discipline as the company navigates current uptake patterns and persistent net losses. Intensifying gross-to-net pressures and complex European pricing negotiations suggest a more cautious outlook for RYTELO's global commercial expansion.
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)
Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. GERN announced a restructuring in December and gave some financial guidance in January, including guidance for 2026 Rytelo net product revenues of $220M-$240M. GERN's IMpactMF study of imetelstat in myelofibrosis is expected to reach an interim analysis in 2026; the existence of that interim could trigger a run-up in the stock.
